INSILICO (03696.HK) signs AI drug R&D pact with Luoxin Pharmaceutical
- The agreement was signed by Insilico's wholly-owned Shanghai subsidiary and Luoxin Pharmaceutical (002793.SZ).
- Focus areas are gastrointestinal, metabolic and other non-oncology chronic diseases, pursued on a phased, project-by-project basis.
NewTimeSpace News: On 13 November 2026, InSilico Medicine Cayman TopCo (stock code: 03696) said its wholly-owned subsidiary Insilico Medicine Technology (Shanghai) Co., Ltd. signed a strategic cooperation agreement with Luoxin Pharmaceutical Group Stock Co., Ltd. (SZSE: 002793) for a long-term partnership on innovative drug R&D, combining artificial intelligence with disease expertise, research data and development experience.
The parties will focus first on gastrointestinal, metabolic and other non-oncology chronic diseases, expanding to other agreed areas as work progresses, on a basis of joint assessment, phased implementation and project-by-project confirmation. Cooperation covers disease research and target discovery, novel molecule discovery and optimisation, enabling ongoing programmes, R&D translation and technical exchange. The Company said the agreement reflects strategic intent only; detailed terms remain subject to further negotiation and definitive documents.
- INSILICO (03696.HK): First-in-Human ISM6331 Data Show 40% ORR in 130mg Mesothelioma Cohort
- ILUVATAR COREX (09903.HK): banking facilities over RMB12 billion granted, over 80% unutilized, supporting business expansion
- INSILICO (03696.HK): Servier AI drug discovery milestone hit
- INSILICO (03696.HK): Nominates ISM9546 as 35th Preclinical Candidate
- INSILICO (03696.HK): Nominates GIPR antagonist ISM1354 as PCC
